Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22824497 | 0.68 | GRM5 (0.36) | — | |
| SCHEMBL7914336 | 0.64 | CCR1 (0.32) | CCR1RAB9ACCR5 | |
| SCHEMBL22824562 | 0.63 | ALDH1A1 (0.34) | — | |
| SCHEMBL6489262 | 0.62 | — | — | |
| SCHEMBL7922389 | 0.60 | HTR2A (0.40) | CCR1RAB9ACCR5 | |
| SCHEMBL15307704 | 0.60 | LMNA (0.44) | CCR1CCR5 | |
| SCHEMBL19145636 | 0.60 | — | — | |
| SCHEMBL13662468 | 0.59 | S100A4 (0.32) | S100A4CCR1RAB9ACCR5 | |
| SCHEMBL20751640 | 0.58 | S100A4 (0.31) | S100A4CCR1RAB9ACCR5 | |
| SCHEMBL4253493 | 0.58 | PDE10A (0.45) | CCR1RAB9ACCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108690053-A | Heteroaryl compound and its application method | 桑诺维恩药品公司 | 2018-10-23 | — | — | CN | disclosed |
| EP-2925762-B1 | TRIAZOLO-PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | SUNOVION PHARMACEUTICALS INC (US) | 2017-07-05 | — | — | EP | disclosed |
| EP-2925762-B1 | TRIAZOLO-PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | SUNOVION PHARMACEUTICALS INC (US) | 2017-07-05 | — | — | EP | disclosed |
| US-9670230-B2 | Heteroaryl compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2017-06-06 | — | — | US | disclosed |
| CN-105051042-A | Triazolo-pyrazine derivatives useful in the treatment of central nervous system disorders | SUNOVION PHARMACEUTICALS INC | 2015-11-11 | — | — | CN | disclosed |
| US-20150291626-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2015-10-15 | — | — | US | disclosed |
| EP-2925762-A1 | TRIAZOLO-PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | Sunovion Pharmaceuticals Inc. (US) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014085284-A1 | TRIAZOLO-PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | SUNOVION PHARMACEUTICALS INC. (US) | 2014-06-05 | — | — | WO | disclosed |
| WO-2014085284-A1 | TRIAZOLO-PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | SUNOVION PHARMACEUTICALS INC. (US) | 2014-06-05 | — | — | WO | disclosed |
| EP-2049490-A1 | N-(BENZOYL)-O- [2- (PYRIDIN- 2 -YLAMINO) ETHYL]-L-TYROSINE DERIVATIVES AND RELATED COMPOUNDS AS A5B1 ANTAGONISTS FOR THE TREATMENT OF SOLID TUMORS | Astra Zeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| WO-2007141473-A1 | N-(BENZOYL)-O- [2- (PYRIDIN- 2 -YLAMINO) ETHYL] -L-TYROSINE DERIVATIVES AND RELATED COMPOUNDS AS A5B1 ANTAGONISTS FOR THE TREATMENT OF SOLID TUMORS | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007141473-A1 | N-(BENZOYL)-O- [2- (PYRIDIN- 2 -YLAMINO) ETHYL] -L-TYROSINE DERIVATIVES AND RELATED COMPOUNDS AS A5B1 ANTAGONISTS FOR THE TREATMENT OF SOLID TUMORS | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291626-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | S100A4 4547/4885CCR1 3722/4885RAB9A 957/4885 |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ITGB5, ITGB1, ITGA2B | S100A4 256/4885CCR1 2135/4885RAB9A 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.